History

2018
Apr
  • A revised publication about anti-fibrosis substance has been
    reported on bioRxiv an online scientific journal
Feb
  • A new substance patent application for ONG43001 has been
    filed on KIPO
2017
Apr
  • A new use patent for ONG21001 & it's derivatives as
    a anti-fibrosis drug has been granted by KIPO (10-1780456)
Feb
  • A research results about the drug candidate for lung fibrosis
    was released to YTN news which is a Korean press
  • The certification for qualified venture company has been
    granted by the Korea government (NO. 20170400190)
  • A publication about anti-fibrosis substance research has
    been reported on bioRxiv an online scientific journal
  • A patent application for cell line for anti-fibrosis research
    has been filed on KIPO&PCT
2016
Dec
  • The company research institute has been certified by the
    Korea government for qualified facilities & personnel
    (No. 2016115796)
Nov
  • A new use patent for ONG21001 & It's derivatives has been filed on USPTO
  • A FTO research has been conducted in the US region for The patent for ONG21001 & It's derivatives “Positive results on Novelty & Inventive”
Sep
  • A revised new use patent for ONG21001 & It's derivatives
    has been filed on KIPO & PCT
Jul
  • A new Head office & company research institute have been
    established in Gasandital-dangi district.
May
  • A new use patent application for ONG21001 & It's
    derivatives as a anti-fibrosis drug has been filed on KIPO
2015
Mar
  • A publication about osteoporosis treatment was
    highlighted by the ASBMB
May
  • A patent for osteoporosis treatment has been granted
    by KIPO (10-1522729)
Ocb
  • A patent for osteoporosis treatment has been granted
    by KIPO (10-1564170)
Nov
  • A patent application for Osteoporosis treatment has
    been filed on USPTO
2014
Aug
  • A patent for osteoporosis treatment has been granted
    by KIPO (10-1433794)
2013
Sep
  • Company founded